Other side effects were stomach upset, palpitations, diarrhea and vomiting, stiff muscles and cramps, and nonspecific intolerance, each in 1 individual

Other side effects were stomach upset, palpitations, diarrhea and vomiting, stiff muscles and cramps, and nonspecific intolerance, each in 1 individual. work or retired with no or mild limitations in daily living. The remaining patients were working part-time, on sick leave, or retired with severe limitations. Conversation and conclusion The majority of MG patients are doing well with currently available treatments, but often at the cost of side effects in the short and in the long term. A significant group is in need of better treatments. Keywords: Myasthenia gravis, Treatment, Autoantibodies, Electromyography Introduction This is an exciting time for patients with myasthenia gravis (MG) and their physicians, as several new treatments with new mechanisms Mouse monoclonal to ESR1 of action exceeded clinical trials and will be available shortly [1]. MG is the most common disorder affecting the neuromuscular junction [2]. It is an autoimmune disease in which autoantibodies are directed against proteins in the postsynaptic membrane, mainly against the acetylcholine receptor (AChR). Despite the presence of symptomatic and several immunomodulatory therapies that resulted in a dramatic decrease of mortality [3], a group of patients are resistant to treatment and the disease has a severe impact on their quality of life [4]. It is important to elucidate which patients could benefit from these new therapies to design treatment protocols. Data around the development of MG in the Belgian populace under the currently available treatments, their efficacy and their side effects is not available. Therefore, we retrospectively examined the files of all MG patients seen at the Neurology Department of Antwerp University or college Hospital during the years 2019, 2020 and 2021. Materials and methods We examined the files of all patients who experienced a neurology discussion in 2019, 2020 and 2021 with a diagnosis of MG or with suspicion of MG. The diagnosis of MG was retained in patients with compatible symptoms and supported by the presence of autoantibodies against AChR or muscle mass specific kinase (MuSK) and/or disturbed neuromuscular transmission on electromyography (EMG). In a few patients, the diagnosis was based on common symptoms, exclusion of other pathology and sustained reaction to pyridostigmine or prednisolone. Patients with congenital myasthenic syndrome, patients with Lambert-Eaton myasthenic syndrome and thymoma patients without symptoms or indicators of myasthenia were not included. The patients were classified according to the Myasthenia Gravis Foundation of America (MGFA) clinical classification at both the time of diagnosis and at the moment of maximum disease severity [5]. At the latest visit, we recognized patients without symptoms of MG and with normal clinical examination, BMPS including patients in complete stable remission and pharmacological remission according to the MGFA-Post Intervention Level (PIS) [5]. Patients with minimal manifestations (no symptoms but minor abnormalities upon clinical examination) were also identified. BMPS The remaining patients were classified according to their MGFA class at last visit. AChR antibodies were assayed with the radioimmunoassay of RSR Ltd. at the Leiden University or college Hospital in the majority of patients, and with a commercial enzyme-linked immunosorbent?assay of Euroimmun in a minority. A few patients experienced a cell based assay with combined screening of antibodies against AChR, MuSK and low-density lipoprotein receptor-related protein 4 (LRP4) in Oxford [6]. EMG assessments of neuromuscular transmission included repetitive nerve stimulations and jitter measurements with a concentric needle electrode under axonal activation [7]. For simplicity this latter test is called single fiber electromyography (SFEMG) in this paper. BMPS Results Patients The diagnosis of myasthenia gravis was retained in 163 patients. The sex and age at diagnosis are shown in Fig.?1. There was a slight preponderance of women (53%). The majority of patients (58%) were older than 50?years at diagnosis and there was an age peak between 60 and 70 in both sexes..